title: Glucose-lowering therapy after myocardial infarction: more questions than answers.
abstract: This editorial refers to The impact of glucose-lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial by L.G. Mellbin et al., on page 166 and Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart by M. Alselmino et al., on page 177
authors.forename: Peter W
authors.initials: PW
authors.lastname: Radke
authors.forename: Heribert
authors.initials: H
authors.lastname: Schunkert
mesh_terms: D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000401:mortality; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents